symp1

0

R. Shah (U.K.): Drug-induced prolongation of the QT Interval: Why the regulatory concern?

D. Escande (France): Preclinical in vivo strategies to identify the risk of an NCE to prolong the QT interval in man.

F. de Clerck (Belgium): In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to preclinical cardiovascular safety pharmacology of an NCE.

J. Camm (U.K.): Strategies to maximise detection risk of QT interval prolongation before the appoval of an NCE: clinical trial designs, techniques of measurements and pitfalls.

R. Shah (U.K.): Regulatory dilemmas and implications for approval and labelling of an NCE.